4E2RCAT是一种eIF4E-eIF4G相互作用的抑制剂，IC50为13.5 μM。

4E2RCat is an inhibitor of eIF4E-eIF4G interaction (IC50 = 13.5 μM) and is capable of blocking coronavirus replication as monitored by viral protein expression and the production of infectious virus.

4E2RCat prevents the interaction between eIF4E (the cap-binding protein) and eIF4G (a large scaffolding protein), inhibiting cap-dependent translation. It significantly decreases human coronavirus 229E (HCoV-229E) replication, reducing the percentage of infected cells and intra- and extracellular infectious virus titers. 4E2RCat inhibits cap-dependent translation in a dose-dependent manner. 4E2RCat inhibits cap-dependent FF translation but not EMCV IRES-driven Ren translation. 4E2RCat inhibits coronavirus replication in a dose- and time-dependent manner[1].

4E2RCat inhibits protein synthesis in vivo and it is not a consequence of increased cell death[1].

432499-63-3

C22H14ClNO4S2

455.93

DMSO:15.5 mg/mL (34.00 mM),Need ultrasonic and warming
Powder: -20°C for 3 years
In solvent: -80°C for 2 years